BACKGROUND/OBJECTIVES: Lower circulating polyunsaturated fatty acids (PUFAs) may induce loss of heart function. We investigated whether lower concentrations of n-3 and n-6 PUFAs were associated with less favourable echocardiographic measures and higher heart rate in older Caucasians, cross-sectionally and after 7 years of follow-up. SUBJECTS/METHODS: We used data from the Hoorn Study, a population-based cohort. Cross-sectional data were available for 621 participants and longitudinal data for 336 participants. Mean age was 68.6 ± 6.8 years at baseline. We performed linear regression analyses using n-3 and n-6 PUFAs quartiles-assayed by gas liquid chromatography-with left ventricular ejection fraction (LVEF), left ventricular mass index, left atrial volume index and heart rate. RESULTS: In multivariable analyses (regression coefficient (95% confidence interval)), the lowest eicosapentaenoic acid and docosahexaenoic acid quartiles compared with the highest quartiles were cross-sectionally associated with lower LVEF. Lower eicosapentaenoic acid and docosahexaenoic acid concentrations were associated with higher heart rate: 3.7 b.p.m. (1.5, 6.0; P for trend o0.001) and 3.4 b.p.m. (1.2, 5.6; P for trend 0.001), respectively. Multivariate longitudinal analyses showed a significant trend across quartiles for alpha-linolenic acid in relation to LVEF. The lowest linoleic acid quartile was significantly associated with a decreased LVEF of À 4.0% compared with the highest quartile. CONCLUSIONS: This study found no strong evidence of longitudinal associations of eicosapentaenoic acid and docosahexaenoic acid with echocardiographic measures, however, lower concentrations of alpha-linolenic acid and linoleic acid were associated with decreased LVEF. These results provide evidence for a potential protective role of alpha-linolenic acid and linoleic acid in relation to systolic function.
INTRODUCTION
Over the past two decades, mortality rates from cardiovascular disease (CVD) have declined, however, survivors often develop loss of heart function in the following years. 1 Consequently, the prevalence of heart failure is expected to rise in the coming years. 2, 3 Despite medical progress, improved treatment and increased survival from myocardial infarction, no substantial change in the prognosis of heart failure has been established and heart failure remains a major public health burden. 4 Therefore, the identification of modifiable factors that influence loss of heart function is important for cardiac disease prevention.
Results of controlled trials in high-risk patients indicate that n-3 polyunsaturated fatty acids (PUFAs; eicosapentaenoic acid and docosahexaenoic acid) supplements improved blood pressure, left ventricular ejection fraction (LVEF), vagal tone, myocardial efficiency and decreased inflammation, and may therefore have a role in the maintenance of heart function. [5] [6] [7] [8] A meta-analysis of randomized controlled trials showed that fish oil-a major source of PUFAs-reduced heart rate. 9 Cross-sectional analyses from the Multi-Ethnic Study of Atherosclerosis showed positive associations between docosahexaenoic acid and LVEF in men, and a positive association between docosahexaenoic acid and left ventricular mass in women, 10 whereas no significant associations were found between plasma n-6 PUFAs (linoleic acid and arachidonic acid) and cardiac magnetic resonance imaging measures. However, in a recent study, higher plasma n-6 PUFAs were inversely related to incidence of coronary heart disease. 11 A recent meta-analysis suggested that plasma and dietary n-3 PUFAs are associated with lower incidence of heart failure in prospective studies. 12 Although these results are promising, most studies estimated dietary intake of n-3 PUFAs using questionnaires and actual n-3 PUFA levels were not assessed. Circulating fatty acids can be objectively measured to determine fatty acid status, 13 this incorporates the influence of absorption and metabolism. Prospective associations between circulating PUFAs and different aspects of cardiac structure and function have rarely been studied and represent a relevant step in unravelling the role of PUFAs in the development of CVD.
In this study, we tested the hypothesis that lower concentrations of alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, linoleic acid and arachidonic acid were associated with less favourable levels of a range of measures of cardiac structure and function, and heart rate both cross-sectionally and after 7 years of follow-up in older men and women.
MATERIALS AND METHODS

Study population
The Hoorn Study is a prospective cohort of men and women aged 50-75 years (n ¼ 2484), which started in 1989. Detailed descriptions of the study concept have been previously published.
14 In the year 2000, all participants who were diagnosed with type 2 diabetes (n ¼ 176) and random samples of participants with normal (n ¼ 705) and impaired (n ¼ 193) glucose metabolism were invited. Of the 1074, 648 (60%) participated. In addition, we invited participants diagnosed with type 2 diabetes (n ¼ 217) from the Hoorn Screening Study, of whom 188 (87%) participated. 15 The study involved 836 participants who had examinations between 2000 and 2001 (considered baseline). 16 Participants without serum PUFAs measurements (n ¼ 114) were excluded from analyses. To maintain the reliability of echocardiographic data, we excluded participants with baseline heart rate 490 b.p.m. (n ¼ 91) or with baseline atrial fibrillation based on ECG codes 8-3-1 to 8-3-4 (n ¼ 10). Participants with incomplete echocardiographic data (n ¼ 1) were also excluded. These exclusions resulted in 621 participants with complete data for serum PUFAs and cardiac measures for cross-sectional analyses.
In 2007-2009, after a median follow-up of 7.0 years (range 6.0-9.0), repeat measurements were performed. Participants without satisfactory echocardiographic data at baseline (n ¼ 40), and participants who were mentally incompetent to participate (n ¼ 12) were excluded, 129 participants died, and 214 could not participate. This resulted in 441 participants eligible for follow-up assessment. Sixty-one (14%) of these were excluded in the present analyses because of no assessment of serum PUFAs. Participants with baseline heart rate 490 b.p.m. (n ¼ 21), baseline atrial fibrillation (n ¼ 4), follow-up heart rate 490 b.p.m. (n ¼ 7) or follow-up atrial fibrillation (n ¼ 12) were excluded. This resulted in 336 participants with heart rate measures. To calculate echocardiographic measures, participants with incomplete data were excluded. This resulted in complete data for LVEF (n ¼ 248), left ventricular mass index (LVMI; n ¼ 257) and left atrial volume index (LAVI; n ¼ 274).
The study complied with the Declaration of Helsinki and written informed consent was obtained from all participants.
Determination of fatty acid profile in serum total lipids A fasting blood sample was drawn at baseline and stored at -80 1C. Fatty acid profiles in serum total lipids were assayed by gas liquid chromatography with flame ionization detection at AS Vitas, Oslo Innovation Center, Oslo, Norway. Serum samples, thawed in the fridge overnight, were vortexed, centrifuged and transferred into new vials. Internal standard triheptadecanoin was added and fatty acids were methylated into methyl esters (FAMEs) with MeOH HCl and extracted with hexane. After neutralization with KOH in water, mixing and centrifuging, the hexane phase was injected into the gas liquid chromatography with flame ionization detection. Analyses were performed on an Agilent 7890A GC with a splitless injector, a 7683B automatic liquid sampler and flame ionization detection (Agilent Technologies, Palo Alto, CA, USA). Separations were obtained using a SP-2380 column (30 m*0.25 mm i.d*0.25 mm film thickness) from Supelco (Bellafonte, PA, USA). Fatty acid content was calculated based on the area percentage of peaks and response factors relative to 18:0. An external standard containing known amounts of relevant FAMEs (Supelco 37 component FAME Mix) was included in each run to correct for differences in fatty acid response factors. The method was validated according to US Food and Drug Administration Guidance Document on Bioanalytical Method Validation. The inter-assay coefficient of variation varied between 2 and 4%.
Cardiac measures
Echocardiography was performed at both assessments by an experienced research technician unaware of the participants' clinical status with the use of an HP SONOS 5500 ultrasound system (2-4 MHz transducer) according to a standardized protocol consisting of two-dimensional, M-mode assessment. 17 Each echocardiogram was inspected by a senior cardiologist. Briefly, we used estimates of LVMI (g/m 2.7 ) to estimate cardiac structure. Higher LVMI is considered an independent predictor of incident heart failure. 18 Systolic function was determined based on LVEF (%), which reflects the capacity of the heart to pump blood into the aorta. As a measure of diastolic function, LAVI (ml/m 2 ) was used. Left atrial enlargement is predictive of future stroke, atrial fibrillation and mortality. 19 In addition, after 15 min of supine rest to reach steady state, we obtained heart rate (b.p.m.) during three consecutive 4 s measurements, triggered by the R-top of a simultaneously recorded electrocardiogram.
Additional measurements
We measured blood pressure, high-density lipoprotein and low-density lipoprotein cholesterol, triglycerides and body mass index as described elsewhere. 16 Hypertension, prior CVD 15 and an estimate of kidney function-glomerular filtration rate-were calculated as previously described. 20 All participants, except those with previously diagnosed diabetes, underwent a standard 75 g oral glucose tolerance test to assess glucose status and were then classified into normal, impaired glucose metabolism or type 2 diabetes according to the 2006 World Health Organization criteria. 21 Participants filled out questionnaires to obtain information on medication use, smoking status, education level and physical activity. 16, 22 Statistics Baseline characteristics are presented by quartiles of serum total n-3 PUFAs and explored by means and standard deviations or, in case of proportions, by numbers. We conducted test for trends across quartiles using linear regression analyses. For categorical variables, we performed a chi-square test to examine differences.
We constructed linear regression models to assess the associations of serum PUFA quartiles with LVEF, LVMI, LAVI and heart rate. The highest quartile of n-3 and n-6 PUFAs was considered as the reference group. Regression coefficients (B) and 95% confidence intervals were reported after adjustment for potential confounders. Minimally adjusted (age, sex, education, smoking status and body mass index) and fully adjusted models with additional adjustment for high-density lipoprotein cholesterol, medication use (anti-hypertensive, lipid-lowering drugs), systolic blood pressure, physical activity, glucose status and prior CVD were used to examine the relationships. Possible confounders for inclusion in the fully adjusted models were assessed based on clinical relevance, or based on associations with exposures or outcomes in the current data set. In case of longitudinal analyses, models were extended by adding baseline values as independent variables to the multivariate regression models (that is, the longitudinal association between alpha-linolenic acid and LVMI was adjusted for baseline LVMI).
The influence of prior CVD, glucose status and sex on the associations of individual n-3 and n-6 PUFAs with LVEF, LVMI, LAVI and heart rate was investigated by including interaction terms. When significant interactions were found, analyses were stratified accordingly. We adopted the level of statistical significance adjusted for multiple interaction testing (Po0.01), to reduce the probability of a type I error. All other P-values were two-tailed (a ¼ 0.05). Data were analyzed with IBM SPSS 20.0 for Windows 07 (SPSS Inc., Chicago, IL, USA).
RESULTS
Baseline data were available for 621 participants with a mean age of 68.6 years, 52% of whom were female. Mean serum total n-3 PUFAs was 3.2 ± 1.3 g/100 g FAME and mean serum n-6 PUFA was 32.3±3.9 g/100 g FAME. Participants in the lowest total n-3 PUFAs quartile were younger, more likely to have type 2 diabetes, and had less favourable lipoprotein profile (Table 1) . We did not find significant interactions with prior CVD, glucose status or sex on any of the associations of n-3 and n-6 PUFAs with LVEF, LVMI, LAVI and heart rate (P40.021).
All multivariable analyses are described in more detail in the online supplement. None of the n-3 or n-6 PUFAs were associated with LAVI (data not shown).
n-3 PUFAs Alpha-linolenic acid. No significant cross-sectional associations were observed between alpha-linolenic acid and echocardiographic measures or heart rate ( Table 2, Supplementary Table 1) . In longitudinal analyses, a significant trend across alpha-linolenic acid quartiles was observed in the fully adjusted model in relation to LVEF (P for trend ¼ 0.015). Also, alpha-linolenic acid showed an inverse trend for LVMI in unadjusted analyses, however, after adjustments the trend became borderline significant (P for trend ¼ 0.056). No other significant associations were observed.
Eicosapentaenoic acid. In cross-sectional analyses, the lowest eicosapentaenoic acid quartile compared with the highest eicosapentaenoic acid quartile was associated with higher heart rate: 4.1 b.p.m. (1.9, 6.2; P for trend o0.001). Full adjustments attenuated the results slightly: 3.7 b.p.m. (1.5, 6.0; P for trend o0.001), but the association was maintained ( Table 2,  Supplementary Table 2 ). Lower concentrations of eicosapentaenoic acid were also associated with lower LVEF in a basic model: -2.1% (-3.9, -0.3; P for trend ¼ 0.009). After full adjustments, the difference between the lowest versus the highest quartile was no longer significant: -1.7% (-3.5, 0.1), however, the trend remained significant ( Table 2, Supplementary Table 2 ). Eicosapentaenoic acid was not cross-sectionally associated with LVMI. After 7 years of follow-up, no significant associations between eicosapentaenoic acid concentrations and echocardiographic measures or heart rate were observed. Docosahexaenoic acid. Results showed significant cross-sectional associations between the lowest docosahexaenoic acid quartile compared with the highest quartile for LVEF and heart rate ( Table 2, Supplementary Table 3) . The basic adjusted model showed that lower docosahexaenoic acid concentrations were associated with lower LVEF: -2.1% (-3.9, -0.3; P for trend ¼ 0.026). Further adjustments attenuated the association: -1.8% (-3.6, 0.0; P for trend ¼ 0.050). The lowest quartile was associated with higher heart rate: 3.0 b.p.m. (0.8, 5.2; P for trend ¼ 0.002) and this association became stronger in the fully adjusted model: 3.4 b.p.m. (1.2, 5.6; P for trend ¼ 0.001). Docosahexaenoic acid concentrations were cross-sectionally not associated with LVMI. No longitudinal associations were observed for docosahexaenoic acid in relation to any of the cardiac measures.
n-6 PUFAs Linoleic acid. Cross-sectionally, lower linoleic acid concentrations compared with higher concentrations were associated with greater LVMI in unadjusted analyses. The associations lost their significance after adjustment for possible confounders. No other cross-sectional associations were observed (Table 3,  Supplementary Table 4) . In longitudinal analyses, the lowest linoleic acid quartile compared with highest linoleic acid quartile was associated with decreased LVEF in a basic model: -4.4% (-8.0, -0.9). After full adjustments, the results attenuated only slightly: -4.0% (-7.8, -0.2), however, there was no significant trend across quartiles. Furthermore, lower linoleic acid concentrations were associated with higher LVMI in unadjusted analyses, Table 1 . Baseline characteristics by quartiles of serum total n-3 polyunsaturated fatty acids in 621 older participants a Serum total n-3 polyunsaturated (g/100 g) P for trend Baseline characteristics are presented as mean±standard deviation or percentages per total serum n-3 polyunsaturated, with their corresponding P for trend values.
PUFAs Linear regression analyses were used to compute unstandardized regression coefficients (B) and their 95% confidence intervals, and P for trend values. Cross-sectional data were available for 621 participants. Follow-up data were available for LVEF (n ¼ 248), LVMI (n ¼ 257) and heart rate (n ¼ 336).
b Mean values ± standard deviation.
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however, lost its significance after basic adjustment. Linoleic acid was not associated with heart rate.
Arachidonic acid. In cross-sectional analyses, arachidonic acid was not associated with LVEF, LVMI or heart rate ( Table 3,  Supplementary Table 5 ). Longitudinal analyses indicated a significant association for lower arachidonic acid concentrations in relation to lower LVMI in unadjusted analyses. The association became nonsignificant after basic adjustment. No other associations were observed.
DISCUSSION
In the present study, we investigated cross-sectional and longitudinal associations between n-3 PUFAs and n-6 PUFAs in relation to LVEF, LVMI, LAVI and heart rate. As expected, lower eicosapentaenoic acid and docosahexaenoic acid concentrations were cross-sectionally associated with both lower LVEF and higher heart rate in fully adjusted models. We did not observe any other cross-sectional associations. In longitudinal analyses, lower concentrations of alpha-linolenic acid were associated with decreased LVEF. In addition, lower alpha-linolenic acid concentrations were longitudinally associated with higher LVMI, but the trend across quartiles was not robust after additional adjustment for potential confounders. Regarding the n-6 PUFAs, the lowest linoleic acid quartile was longitudinally associated with a decrease in LVEF of -4%, however, the trend across quartiles was not statistically significant. Our results indicate that lower alphalinolenic acid and linoleic acid were associated with decreased systolic function and may help to prevent loss of heart function. Our cross-sectional results are in line with an earlier crosssectional study in older adults that higher fish consumption was associated with lower heart rate and lower prevalence of reduced ejection fraction. 23 Fish consumption was not associated with other cardiac measures including left ventricular mass and left atrial volume, which is comparable with our findings. In the MultiEthnic Study of Atherosclerosis, cross-sectional associations between plasma n-3 and n-6 PUFAs in relation to cardiac 63.5 ± 9.9 62.6 ± 9.7 62.6 ± 10.0 0.275 Linear regression analyses were used to compute unstandardized regression coefficients (B) and their 95% confidence intervals, and P for trend values. Cross-sectional data were available for 621 participants. Follow-up data were available for LVEF (n ¼ 248), LVMI (n ¼ 257) and heart rate (n ¼ 336). PUFAs and echocardiographic measures I Reinders et al magnetic resonance imaging did not indicate significant associations. 10 However, stratification by sex revealed a positive association between docosahexaenoic acid and left ventricular mass in women and higher docosahexaenoic acid concentrations tended to be associated with increased LVEF in men. We did not observe effect modification by sex. Their contradictory results compared with our results might be due to the healthier, younger population or difference in PUFAs concentrations. Our crosssectional results for alpha-linolenic acid, linoleic acid and arachidonic acid are in line with their null findings.
Several RCTs have investigated the effects of long-term (41 year) supplementation of n-3 PUFAs with different cardiac measures. These trials showed that supplementation of either 1 or 2 g/d of n-3 PUFAs increased LVEF in heart failure patients 6, 7 and these results were confirmed by a small dose-response study. 24 The anti-inflammatory properties of n-3 PUFAs might prevent remodelling, 25 and therefore may positively affect systolic function. Our cross-sectional results for heart rate are in line with a meta-analysis of randomized controlled trials in which they found that fish oil reduces heart rate. 9 The positive effects of n-3 PUFAs on heart rate might be explained by improved cardiac electrophysiology. 9 However, our results did not provide strong indications for associations of a higher eicosapentaenoic acid and docosahexaenoic acid status and better cardiac electrophysiologic measurements. In contrast, our longitudinal analyses revealed not even significant associations between eicosapentaenoic acid and docosahexaenoic acid concentrations with heart rate. The more homogenous and smaller groups in the longitudinal analyses decreased the power to show associations. However, the lowest linoleic acid quartile was associated with lower LVEF after 7 years of follow-up. A large epidemiological study indicated that plasma n-6 PUFA-especially linoleic acid-concentrations were inversely related to subsequent risk of incident coronary heart diseases. 11 Conflicting results were observed in a recent updated meta-analysis about replacing saturated fat with n-6 PUFAs for secondary prevention. Authors reported a non-significant increased risk of death from coronary heart diseases and CVDs. 26 Included trials were performed in cardiac patients, and trials were not placebo controlled. Therefore, results must be interpreted with caution. In our study population, the distribution of serum PUFAs was comparable with other studies, although mean arachidonic acid concentrations were slightly lower. 27 Differences in mean fatty acid values might therefore be explained by differences in age, disease history or dietary habits.
No other studies have investigated the prospective relationship between circulating PUFAs and subsequent echocardiographic measures. It is therefore difficult to directly compare our results with other findings.
Our study has several strengths. To our knowledge, this is the first prospective study that has investigated the associations between circulating n-3 and n-6 PUFAs and echocardiographic measures. The results provide evidence that lower circulating PUFAs, as compared with higher concentrations, are associated with worse heart function and greater decline in heart function in a general population. Hence, this study represents a relevant step forward towards unravelling the potential role of PUFAs in the pathophysiology of cardiac diseases. We measured the fatty acid profile in total serum lipids as an objective biomarker of individual PUFA exposures, which reflects a dietary intake over the past weeks. 13, 28 The measurement of circulating PUFAs also incorporates potential physiologically relevant processes such as absorption, membrane incorporation and metabolism. 8 Measurements of biomarkers have the additional advantage of allowing direct quantification of the individual n-3 and n-6 PUFAs and therefore to determine their individual relationship with cardiac structure and function. In addition, it removes the potential biases associated with self-reported dietary information. Furthermore, the detailed and standardized collection of demographic, lifestyle and other covariates allowed adjustment for several relevant potential confounders.
Potential limitations should also be considered. Our crosssectional results of eicosapentaenoic acid and docosahexaenoic acid concentrations in relation to LVEF and heart rate in the absence of longitudinal associations might be due to reverse causation, as people with a better heart function might have a healthier lifestyle and consume more fish, and therefore have higher PUFA concentrations. However, based on previous research 6, 7, [9] [10] [11] [12] and our findings, we believe that higher eicosapentaenoic acid and docosahexaenoic acid concentrations have a positive influence on heart function. In case of the longitudinal analyses, the smaller sample size resulted in limited statistical power. Participants with only baseline data had higher prevalence of chronic diseases including type 2 diabetes, prior CVD and/or hypertension, therefore survival bias cannot be excluded. Serum PUFAs were assessed only at baseline and changes in exposure over time can lead to long-term misclassification, most likely leading to underestimation of the associations. Repeated serum PUFA measurements would be of importance to determine changes in PUFA status over time. We tested multiple associations, and therefore some findings might be due to chance and should be replicated in a larger study. Although a single association could be a chance finding, the totality of evidence that supports the association of n-3 and n-6 PUFAs with cardiac measures is unlikely produced by chance alone. Finally, the Hoorn Study comprised older Dutch men and women, and results may not be generalizable to younger populations, in whom pathophysiology may differ compared with older adults. In addition, the Hoorn Study population has an overrepresentation of participants with type 2 diabetes. The analytic sample consisted of 33% participants with type 2 diabetes and therefore limits the external validity to populations with solely normal glucose metabolism.
In conclusion, this study in an older population of men and women showed that lower serum eicosapentaenoic acid and docosahexaenoic acid were cross-sectionally associated with lower LVEF and higher heart rate. Furthermore, lower concentrations of alpha-linolenic acid and linoleic acid were associated with decreased systolic function after 7 years of follow-up. The results provide evidence for a potential protective role of higher alphalinolenic acid and linoleic acid concentrations in relation to systolic function. As this is the first prospective study investigating the benefits of circulating n-3 and n-6 PUFAs on cardiac measures, future prospective studies are needed with a larger sample size and a different study population to replicate our study results to generate a larger body of evidence, which would place our longitudinal findings in context.
